

**Makers Laboratories Limited**

Regd. Office : 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24230MH1984PLC033389

Tel:+91 22 28688544 E-mail : investors@makerslabs.com , Website : www.makerslabs.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2020**


(Rs. In Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
I	Revenue from Operations	913.82	1,253.58	1,024.89	5,139.66
II	Other Income	19.36	12.73	4.44	22.55
III	<b>Total Income (I + II)</b>	<b>933.18</b>	<b>1,266.31</b>	<b>1,029.33</b>	<b>5,162.21</b>
IV	<b>Expenses:</b>				
	a) Cost of materials consumed	110.38	151.64	228.51	782.33
	b) Purchases of stock-in-trade	309.62	348.64	215.00	2,098.46
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(22.23)	129.81	145.17	70.14
	d) Employee benefits expense	194.18	199.68	192.55	783.88
	e) Finance Cost	39.56	26.48	6.86	70.31
	f) Depreciation and amortisation expense	100.10	61.94	37.76	198.75
	g) Other expenses	204.71	268.45	257.03	1,133.44
	<b>Total Expenses (IV)</b>	<b>936.32</b>	<b>1,186.64</b>	<b>1,082.88</b>	<b>5,137.31</b>
V	<b>Profit / (Loss) before tax (III - IV)</b>	<b>(3.14)</b>	<b>79.67</b>	<b>(53.55)</b>	<b>24.90</b>
VI	<b>Tax Expense</b>				
	Current Tax	-	3.82	-	3.82
	Deferred Tax (Asset) / Liability	(4.70)	42.61	8.33	33.46
VII	<b>Net Profit / (Loss) after tax (V-VI)</b>	<b>1.56</b>	<b>33.24</b>	<b>(61.88)</b>	<b>(12.38)</b>
VIII	<b>Other Comprehensive Income</b>				
	a) Items that will not be reclassified to profit & loss	289.47	269.13	(67.71)	408.52
	Less: Tax expenses thereon	35.36	27.74	(7.54)	45.08
	<b>Other Comprehensive Income</b>	<b>254.11</b>	<b>241.39</b>	<b>(60.17)</b>	<b>363.44</b>
IX	<b>Total Comprehensive Income after tax (VII + VIII)</b>	<b>255.67</b>	<b>274.63</b>	<b>(122.05)</b>	<b>351.06</b>
X	Paid-up equity share capital (Face value of Rs.10/- each)	491.70	491.70	491.70	491.70
XI	Other Equity				3,970.23
XII	Earnings per share (of Rs.10/- each) - Not annualised:				
	Basic & Diluted	0.03	0.68	(1.26)	(0.25)

**Notes:**

- The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on August 12, 2020
- The statutory auditors have carried out a limited review of the financial results and have issued their unmodified report thereon.
- The financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- Being manufacturers of pharmaceuticals and providers of essential services, the Company is continuing with its manufacturing and marketing operations strictly following the Covid-19 related guidelines issued by the government from time to time. The Company has considered possible impact of Covid-19 on the carrying amounts of property, plant and equipments, investments, inventories, receivables and other current assets. The Company expects that the carrying amounts of the assets are recoverable and that the Company will continue to have sufficient liquidity to finance its business operations as well as expansion plans. However, the Company's business continues to be impacted due to lower patient footfall in dispensaries, nursing homes and hospitals due to Covid-19 pandemic.
- The figures for the quarter ended March 31, 2020 are the balancing figure between the Audited Figures in respect of full financial year and the reviewed year-to-date figures up to the third quarter of the financial year.
- The Company has only one reportable segment viz. 'Pharmaceuticals'.
- Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

Place : Mumbai,  
Date : August 12, 2020



By Order of the Board  
For Makers Laboratories Limited

*N. N. Jain*  
Nilesh Jain  
Wholetime Director  
(DIN 05263110)

